GAfPA Blog

The GAfPA Patient Advocacy Blog

GAfPA’s Statement Supporting the USMCA Signing at the G20 Summit

A new international treaty has important implications for patients’ access to innovative treatments. On November 30, during the G20 Summit in Buenos Aires Argentina, President Trump, Prime Minister Trudeau and President Peña Nieto signed the new U.S. Mexico Canada Agreement. Once approved by the U.S. Congress, this trade deal will replace NAFTA as the free … Continued

GAfPA Statement on United States-Mexico-Canada Agreement

Patients who are eager for the next generation of treatments and cures will be well served by the United States-Mexico-Canada Agreement.  This agreement provides intellectual property protections that promote patient access to innovative medicine, clearing the way for new treatments for cancer, Alzheimer’s, diabetes and many other conditions.

La farmacovigilancia como modo de reforzamiento de regulaciones

  El viernes 24 de agosto de 2018 se llevó a cabo el primer webinario de la Academia Latinoamericana de Pacientes. La academia tuvo su primera reunión en la ciudad de Miami el 26 de mayo. Este webinario sirvió como un seguimiento de esa reunión. El tema del webinario enfocaba en la farmacovigilancia como modo … Continued

How Latin America Can Avoid a Health Care Misstep

When public health emergencies threaten developing nations, governments may look for cheap, fast ways to secure necessary medicine.  One option is compulsory licensing, the topic of a new “Fast Facts” from the Global Alliance for Patient Access. But how does compulsory licensing work?  And does it really meet patients’ needs? Compulsory licensing occurs when governments … Continued

School’s in Session at the Latin American Patient Academy

Patient advocates from Latin America are about to get schooled – in the best possible way. The first collaborative education program for advocacy leaders, Miami’s Latin American Patient Academy, now offers the only program of its kind in the world. The academy allows advocacy organizations to strengthen their leaders in three areas: Regulations Evaluation of … Continued

Portugal Confirms Patient Role in Treatment Decisions

Do patients have a say in what drug they’re given at hospital? In Portugal, the National Commission for Pharmacy and Therapeutics gave a resounding “yes” this month with a newly released clarification document. The document addresses the use of biosimilars and any switching from a reference product to a biosimilar.  The issue was the subject … Continued

Drug Approval Signals New Options for Stroke, Heart Attack Survivors in Europe

Heart patients in Europe have something to celebrate. This week, the European Commission approved a groundbreaking new drug, evolocumab, to prevent heart attack and stroke for patients who have already survived a cardiac event.  The approval marks the entry of an important new tool for secondary prevention. Evolocumab is a PCSK9 inhibitor, which reduces cardiovascular … Continued

In Europe, Advocates Emphasize Role of Patient Voice

Patient advocacy organisations know the power of the patient voice when it comes to accessing medicine. Just consider Arthritis Ireland.  As highlighted during a recent Global Alliance for Patient Access webinar, the group saw patient input make a difference during the country’s experience with access to lidocaine patches.  The medication numbs the skin to help … Continued

Mapping Report Reveals Access Disparities among European Patients

How accessible is your health care?  It all depends upon where you live, as a new report from the European Federation of Crohn’s & Ulcerative Colitis Associations confirms. With the help of 32 member associations, the federation worked from October 2016 to December 2017 to examine patients’ access to innovative medicine across 31 European countries.  … Continued